CA2923426A1 - Formulations for cgrp receptor antagonists - Google Patents

Formulations for cgrp receptor antagonists Download PDF

Info

Publication number
CA2923426A1
CA2923426A1 CA2923426A CA2923426A CA2923426A1 CA 2923426 A1 CA2923426 A1 CA 2923426A1 CA 2923426 A CA2923426 A CA 2923426A CA 2923426 A CA2923426 A CA 2923426A CA 2923426 A1 CA2923426 A1 CA 2923426A1
Authority
CA
Canada
Prior art keywords
liquid pharmaceutical
pharmaceutical composition
composition according
oxo
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2923426A
Other languages
English (en)
French (fr)
Inventor
Majid Mahjour
Leonardo R. Allain
Sutthilug Sotthivirat
Russell G. Maus
Rebecca NOFSINGER
Lisa LUPTON
Wei Xu
Francis Flanagan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2923426A1 publication Critical patent/CA2923426A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2923426A 2013-09-16 2014-09-11 Formulations for cgrp receptor antagonists Pending CA2923426A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361878183P 2013-09-16 2013-09-16
US61/878,183 2013-09-16
PCT/US2014/055132 WO2015038736A2 (en) 2013-09-16 2014-09-11 Formulations for cgrp receptor antagonists

Publications (1)

Publication Number Publication Date
CA2923426A1 true CA2923426A1 (en) 2015-03-19

Family

ID=52666511

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2923426A Pending CA2923426A1 (en) 2013-09-16 2014-09-11 Formulations for cgrp receptor antagonists

Country Status (13)

Country Link
US (3) US20160220552A1 (cg-RX-API-DMAC7.html)
EP (2) EP3046923A4 (cg-RX-API-DMAC7.html)
JP (1) JP6612234B2 (cg-RX-API-DMAC7.html)
KR (3) KR102337994B1 (cg-RX-API-DMAC7.html)
CN (2) CN112545981A (cg-RX-API-DMAC7.html)
AU (1) AU2014318741B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016005589B8 (cg-RX-API-DMAC7.html)
CA (1) CA2923426A1 (cg-RX-API-DMAC7.html)
IL (1) IL244356B (cg-RX-API-DMAC7.html)
MX (1) MX384611B (cg-RX-API-DMAC7.html)
RU (1) RU2690006C2 (cg-RX-API-DMAC7.html)
SA (1) SA516370737B1 (cg-RX-API-DMAC7.html)
WO (1) WO2015038736A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI487706B (zh) * 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑
HK1232218A1 (zh) 2014-02-05 2018-01-05 Merck Sharp & Dohme Llc Cgrp-活性化合物的片剂制剂
US11717515B2 (en) 2020-12-22 2023-08-08 Allergan Pharmaceuticals International Limited Treatment of migraine
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20210128724A1 (en) * 2019-07-05 2021-05-06 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
CN119350337A (zh) * 2024-12-24 2025-01-24 药康众拓(北京)医药科技有限公司 一类氘代哌啶酮酸酰胺氮杂茚满类cgrp抑制剂药物及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE295167T1 (de) * 1998-03-19 2005-05-15 Merck & Co Inc Schwefelpentafluorophenylpyrazole zur kontrolle von ektoparasitenbefall
GB9815801D0 (en) * 1998-07-21 1998-09-16 Merck & Co Inc Liquid polymeric compositions for controlled released bioactive substances
ITRM20020357A1 (it) * 2002-07-03 2004-01-05 Foscama Biomed Chim Farma Composizione liquida per la somministrazione orale di lorazepam.
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
CN101511184A (zh) * 2006-09-08 2009-08-19 默克公司 用于口服给药cgrp拮抗剂的液体药物制剂
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
TWI487706B (zh) 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑

Also Published As

Publication number Publication date
NZ717327A (en) 2021-10-29
SA516370737B1 (ar) 2021-05-27
BR112016005589B1 (pt) 2022-12-06
US20190070161A1 (en) 2019-03-07
RU2690006C2 (ru) 2019-05-30
IL244356B (en) 2020-09-30
MX2016003394A (es) 2016-10-28
EP3915561A1 (en) 2021-12-01
CN112545981A (zh) 2021-03-26
RU2016114537A3 (cg-RX-API-DMAC7.html) 2018-07-04
KR102337994B1 (ko) 2021-12-13
RU2016114537A (ru) 2017-10-23
KR20210153745A (ko) 2021-12-17
EP3046923A2 (en) 2016-07-27
WO2015038736A2 (en) 2015-03-19
KR20160055149A (ko) 2016-05-17
AU2014318741B2 (en) 2018-12-06
CN105531275A (zh) 2016-04-27
WO2015038736A3 (en) 2015-11-12
MX384611B (es) 2025-03-14
US20160220552A1 (en) 2016-08-04
BR112016005589A8 (pt) 2018-02-06
KR20220108207A (ko) 2022-08-02
US20210330660A1 (en) 2021-10-28
CN105531275B (zh) 2020-12-18
JP2016530316A (ja) 2016-09-29
BR112016005589B8 (pt) 2023-04-18
JP6612234B2 (ja) 2019-11-27
EP3046923A4 (en) 2017-03-22
IL244356A0 (en) 2016-04-21
AU2014318741A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
AU2014318741B2 (en) Formulations for CGRP receptor antagonists
AU2016385362B2 (en) Long acting injectable formulations
JP2002526424A (ja) パクリタクセル含有医薬組成物
US20100087392A1 (en) Complexes of ibuprofen, cyclodextrins and ternary agents and the use thereof in pharmaceutics
KR20210087490A (ko) 경구 투여용 에다라본 현탁액
AU2022298186B2 (en) Sustained release formulation composition comprising semaglutide or pharmaceutically acceptable salt thereof
JP2006312651A (ja) オキシカルバゼピン含有懸濁剤
NZ717327B2 (en) Formulations for cgrp receptor antagonists
JP2001316265A (ja) オザグレルナトリウム含有注射液およびその安定化方法
EP2874624B1 (en) Injectable antibiotic formulations and their methods of use
NL2028762B1 (en) Micelle-generating formulations for enhanced bioavailability
KR100896375B1 (ko) 주사용 의약 제제
JP6665057B2 (ja) ボルテゾミブを含有する医薬製剤
EP2874623B1 (en) Injectable antibiotic formulations and their methods of use
NZ613138B2 (en) Injectable antibiotic formulations and their methods of use
NZ613138A (en) Injectable antibiotic formulations and their methods of use
NZ613240B2 (en) Injectable antibiotic formulations and their methods of use
WO2014108791A1 (en) Injectable composition containing chlorothiazide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813

EEER Examination request

Effective date: 20190813